An observational study in Neuromuscular Diseases (NMD), sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Northwestern University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.
Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 2nd largest by planned enrollment of the 46 observational ones that give a count, is one of 10 that started in 2026, is one of 46 observational ones, reaches primary completion later than 37 of the 38 other live ones, and was the 115th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18–70
David Toupin · Sites in United States
Ages 6–12
University of Pennsylvania · Sites in United States
Ages 18+
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
AskBio Inc · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 20
First in 1984; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 72 across 144 observational studies indexed under Neuromuscular Diseases.
Median enrollment 48 across the 72 interventional studies, 82 across the 46 observational. Of the 77 that completed or were terminated, 28 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 120 have an industry lead sponsor. The 10 most frequent:
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Northwestern University has 1 study filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuromuscular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT06970522Shirley Ryan AbilityLabWearable Sensors to Detect Atypical Muscle Activation in Young Infants | 2026-12-31 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07223632Vanda PharmaceuticalsTreatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 120 studies in Neuromuscular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this research is to collect clinical data and tissue samples from adult patients with neuromuscular disease cared for at the Northwestern Memorial Hospital neuromuscular clinic (Lavin Building, 19th floor).
This study has the following aims:
Aim 1: To consent a large cohort of adult study participants with neuromuscular disorders, including but not limited to motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies for participation in the biorepository and to collect longitudinal data on their clinical disease phenotypes.
Aim 2: To obtain and store biological samples from biorepository study participants, including whole blood, plasma, serum, peripheral blood mononuclear cells [PBMCs], skin biopsies, and cerebrospinal fluid.
Aim 3: To develop a data-sharing process to provide de-identified biorepository participant clinical data and samples to partnered investigators to expedite discovery in neuromuscular disease diagnosis and treatment.
Northwestern University and the associated Northwestern Memorial Hospital serve a nexus of clinical care and translational research in neuromuscular disease. A significant opportunity exists within the division to develop a robust Neuromuscular Disease Biorepository (NDB) in which carefully-phenotyped patient biofluid samples are catalogued and made readily available to partnered basic and translational scientists both within and outside of the Northwestern academic community.
The overarching hypothesis underpinning the Northwestern Disease Biorepository is that longitudinally sampled participant biosamples paired to refined clinical and paraclinical phenotypic data will accelerate basic and translational scientific discovery both locally at Northwestern and ultimately in the larger research community. This is imperative in the world of neuromuscular disease, where effective treatments are emerging yet all too rare, and understanding of disease mechanisms is still in a fledgling state for most conditions.
Procedures:
A possible participant will be identified by minimal risk screening activities by the biorepository principal investigator or delegated co-investigators. Screening activities include routine chart review including clinical notes, laboratory and radiologic investigations, pathology reports, and completed genetic testing. After a possible participant has been identified, they will be consented by a biorepository investigator using the IRB-approved informed consent form (ICF). Consented participants will then complete a clinical data questionnaire (IRB-approved data collection tool) specifically designed to allow biorepository investigators to rapidly and accurately phenotype the wide-spectrum of neuromuscular disease encountered in routine clinical care. Blood samples will be obtained by trained repository staff. Blood samples will be routinely processed into plasma and serum; additional processing for RNA extraction and peripheral blood mononuclear cells will be completed at the investigator's discretion. Cerebrospinal fluid (CSF) sampling is optional; Lumbar puncture will be completed by a qualified investigator as described in the NU IRB protocol. CSF samples can also be obtained in the event of an indicated lumbar puncture during routine clinical care or as an adjunct to other ongoing studies within the NU/NM neuromuscular division where permitted by the specific study protocol. Clinical data questionnaires and samples will be obtained every six months where feasible.
To obtain access to biorepository samples, an interested research group must contact a biorepository investigator and provide a scientific proposal describing their hypotheses and specific use of provided biosamples. Requests will be sent to the PI Dr. Donaghy at Ryan.Donaghy@nm.org. Requests will be approved by the protocol detailed in the Biorepository Scientific Validity Review Committee Standard Operating Procedure (SVRC SOP). Unless a requesting research group has already received an IRB approved proposal that allows for sharing of protected health information (PHI) by HIPAA rules, research samples will be provided without any of the 18 established PHI content as described in the SOP. The provision of non-PHI-containing research materials to requesting researchers is approved by Northwestern University-IRB.
Neuromuscular Diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biospecimen Samples
This is a longitudinal registry of biofluid samples paired to categorized clinical data ultimately used to provide sample to partnered basic scientists and accelerate discovery in neuromuscular medicine.
Time frame: 50 years
Plan to share: Yes
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Mar 2050, 286 months after the start.
Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's planned 286 months is above that.
Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.